Lilly’s Bloom: A Fleeting Perfection?

by

The triumph of Eli Lilly (LLY 0.06%) in the realm of GLP-1 agonists is, admittedly, rather dazzling. To witness Mounjaro and Zepbound ascend with such velocity – a 99% and 175% increase, respectively – is to observe a market captivated, if not entirely seduced. They now constitute a majority – a rather vulgar display, really – of the company’s revenues. One might almost suspect a conspiracy of waistlines.

Yet, as with all fleeting beauties, the question arises: is it not already too late to acquire a share in this particular bloom? The market, you see, has a regrettable habit of mistaking present success for future immortality. And immortality, dear reader, is a privilege reserved for art, not pharmaceuticals.

A Reign, However Temporary

It is worth noting that Novo Nordisk (NVO 2.07%) was, in fact, the first to venture into this weight-loss arena with Wegovy. But, as is so often the case, being first is merely a prelude to being surpassed. Lilly’s formulations proved, shall we say, more persuasive. This underscores a rather brutal truth of the pharmaceutical world: innovation is a relentless game, and yesterday’s triumph is tomorrow’s footnote.

Novo Nordisk, with admirable haste, has responded with a GLP-1 pill – a decidedly clever maneuver. And where Novo Nordisk leads, Pfizer (PFE +0.13%) is sure to follow. The stage, it seems, is set for a rather spirited competition. To believe that Lilly can maintain its current dominion indefinitely is to indulge in a most unscientific optimism.

The present advantages, of course, are considerable. But patent protections, like all things, are ephemeral. The inevitable arrival of generics will, with predictable efficiency, erode the current profits. To cling to the belief that this will not happen is to mistake a temporary advantage for an eternal truth.

The Price of Adoration

The truly distressing aspect of investing in Eli Lilly at this juncture is not its lack of merit, but the sheer enthusiasm with which the market has already priced in its success. A price-to-earnings ratio of 43x is, shall we say, a rather robust valuation. It is below the company’s historical average, yes, but significantly exceeds that of the S&P 500 index (^GSPC 0.60%) and its peers. One suspects the market is operating on hope, rather than calculation.

There are, naturally, two paths to a more reasonable valuation. The stock price could descend, or earnings could ascend. To achieve the latter, however, would require a truly remarkable performance, given the intensifying competition. The market, it seems, is remarkably adept at ignoring inconvenient truths.

Loading widget...

In essence, Eli Lilly’s share price reflects a rather optimistic narrative, devoid of any hint of skepticism. When its dominance wanes – as it inevitably will – the premium afforded to the stock may deflate with considerable speed. It is a lesson often learned, but rarely heeded.

One should also note the rather modest dividend yield of 0.6%. Value investors, and those who appreciate a tangible return on their investment, will likely find more fertile ground elsewhere. It is a testament to the power of narrative, that so many are willing to forgo immediate gratification for the promise of future growth.

A Word of Caution

The pharmaceutical sector is a crucible of innovation and competition. Industry leaders like Pfizer and Novo Nordisk are already pushing the boundaries of GLP-1 technology. With such a lofty valuation, Eli Lilly leaves little room for error. It is a well-managed company, to be sure, but it is increasingly difficult to justify an investment at this price. One suspects that the opportunity to profit from its GLP-1 success has, for most investors, already passed.

Read More

2026-03-19 18:25